Indicator, Reagent, or Diagnostic Aid
ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair
ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis
Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration
Merck’s WINREVAIR Receives EU Approval for Pulmonary Arterial Hypertension Treatment
WINREVAIR, Merck, EU Approval, Pulmonary Arterial Hypertension, PAH Treatment
Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network
Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals
Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity
Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD
Actinium’s Radioconjugate Faces Setback as FDA Requests New Study
Actinium Pharmaceuticals, radioconjugate, FDA, new study, Iomab-B, regulatory affairs, biotech, cancer treatment
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1